Tags

Type your tag names separated by a space and hit enter

Neurological Aspects of Medical Use of Cannabidiol.
CNS Neurol Disord Drug Targets. 2017; 16(5):541-553.CN

Abstract

BACKGROUND

Cannabidiol (CBD) is among the major secondary metabolites of Cannabis devoid of the delta-9-tetra-hydrocannabinol psychoactive effects. It is a resorcinol-based compound with a broad spectrum of potential therapeutic properties, including neuroprotective effects in numerous pathological conditions. CBD neuroprotection is due to its antioxidant and antiinflammatory activities and the modulation of a large number of brain biological targets (receptors, channels) involved in the development and maintenance of neurodegenerative diseases.

OBJECTIVE

The aim of the present review was to describe the state of art about the pre-clinical research, the potential use and, when existing, the clinical evidence related to CBD in the neurological field.

METHOD

Collection of all the pre-clinical and clinical findings carried out investigating the effects of CBD alone, not in combination with other substances, in the neurological arena with the exclusion of studies on neuropsychiatric disorders.

RESULTS

Laboratory and clinical studies on the potential role of CBD in Parkinson's disease (PD), Alzheimer's disease (AD), multiple sclerosis (MS), Huntington's disease (HD), amyotrophic lateral sclerosis ALS), cerebral ischemia, were examined.

CONCLUSION

Pre-clinical evidence largely shows that CBD can produce beneficial effects in AD, PD and MS patients, but its employment for these disorders needs further confirmation from well designed clinical studies. CBD pre-clinical demonstration of antiepileptic activity is supported by recent clinical studies in human epileptic subjects resistant to standard antiepileptic drugs showing its potential use in children and young adults affected by refractory epilepsy. Evidence for use of CBD in PD is still not supported by sufficient data whereas only a few studies including a small number of patients are available.

Authors+Show Affiliations

Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy.Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Messina, Italy.Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy.Department of Biotechnology and Legal Medicine, University of Palermo, Palermo, Italy.Unit of Forensic Toxicology, Department of Anatomical, Histological, Forensic and Orthopedic Sciences, Sapienza University of Rome, Rome, Italy.National Center of Epidemiology, National Institute of Health, Rome, Italy.National Center of Epidemiology, National Institute of Health, Rome, Italy.Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy. Via Consolare Valeria 1, 98125 Messina, Italy.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

28412918

Citation

Mannucci, Carmen, et al. "Neurological Aspects of Medical Use of Cannabidiol." CNS & Neurological Disorders Drug Targets, vol. 16, no. 5, 2017, pp. 541-553.
Mannucci C, Navarra M, Calapai F, et al. Neurological Aspects of Medical Use of Cannabidiol. CNS Neurol Disord Drug Targets. 2017;16(5):541-553.
Mannucci, C., Navarra, M., Calapai, F., Spagnolo, E. V., Busardò, F. P., Cas, R. D., Ippolito, F. M., & Calapai, G. (2017). Neurological Aspects of Medical Use of Cannabidiol. CNS & Neurological Disorders Drug Targets, 16(5), 541-553. https://doi.org/10.2174/1871527316666170413114210
Mannucci C, et al. Neurological Aspects of Medical Use of Cannabidiol. CNS Neurol Disord Drug Targets. 2017;16(5):541-553. PubMed PMID: 28412918.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Neurological Aspects of Medical Use of Cannabidiol. AU - Mannucci,Carmen, AU - Navarra,Michele, AU - Calapai,Fabrizio, AU - Spagnolo,Elvira V, AU - Busardò,Francesco P, AU - Cas,Roberto D, AU - Ippolito,Francesca M, AU - Calapai,Gioacchino, PY - 2016/11/30/received PY - 2017/01/17/revised PY - 2017/03/08/accepted PY - 2017/4/18/pubmed PY - 2018/5/2/medline PY - 2017/4/18/entrez KW - Cannabidiol KW - neurodegenerative diseases KW - neurological KW - neurology KW - neuroprotection SP - 541 EP - 553 JF - CNS & neurological disorders drug targets JO - CNS Neurol Disord Drug Targets VL - 16 IS - 5 N2 - BACKGROUND: Cannabidiol (CBD) is among the major secondary metabolites of Cannabis devoid of the delta-9-tetra-hydrocannabinol psychoactive effects. It is a resorcinol-based compound with a broad spectrum of potential therapeutic properties, including neuroprotective effects in numerous pathological conditions. CBD neuroprotection is due to its antioxidant and antiinflammatory activities and the modulation of a large number of brain biological targets (receptors, channels) involved in the development and maintenance of neurodegenerative diseases. OBJECTIVE: The aim of the present review was to describe the state of art about the pre-clinical research, the potential use and, when existing, the clinical evidence related to CBD in the neurological field. METHOD: Collection of all the pre-clinical and clinical findings carried out investigating the effects of CBD alone, not in combination with other substances, in the neurological arena with the exclusion of studies on neuropsychiatric disorders. RESULTS: Laboratory and clinical studies on the potential role of CBD in Parkinson's disease (PD), Alzheimer's disease (AD), multiple sclerosis (MS), Huntington's disease (HD), amyotrophic lateral sclerosis ALS), cerebral ischemia, were examined. CONCLUSION: Pre-clinical evidence largely shows that CBD can produce beneficial effects in AD, PD and MS patients, but its employment for these disorders needs further confirmation from well designed clinical studies. CBD pre-clinical demonstration of antiepileptic activity is supported by recent clinical studies in human epileptic subjects resistant to standard antiepileptic drugs showing its potential use in children and young adults affected by refractory epilepsy. Evidence for use of CBD in PD is still not supported by sufficient data whereas only a few studies including a small number of patients are available. SN - 1996-3181 UR - https://www.unboundmedicine.com/medline/citation/28412918/Neurological_Aspects_of_Medical_Use_of_Cannabidiol_ L2 - https://www.ingentaconnect.com/openurl?genre=article&issn=1871-5273&volume=16&issue=5&spage=541&aulast=Mannucci DB - PRIME DP - Unbound Medicine ER -